Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03899649 · ClinicalTrials.gov registry record
A Registry Study of NanoKnife IRE for Stage 3 Pancreatic Cancer
A clinical trial of Stage III Pancreatic Cancer, sponsored by Angiodynamics.
- Active
- Registry status
- 532
- Enrollment target
- 14
- Study locations
NCT03899649 is a study of Stage III Pancreatic Cancer that is active but no longer recruiting, run by Angiodynamics. The registered enrollment target is 532 participants, above the 126-participant average among 13 other Stage III Pancreatic Cancer trials with a reported enrollment target (322% higher). The trial reports 14 study locations across 12 states.
The verdict
NCT03899649, a study of Stage III Pancreatic Cancer, is active but no longer recruiting, sponsored by Angiodynamics.
- ACTIVE NOT RECRUITING
- Registry status
- 532 participants
- Enrollment target
- 14
- Study locations
Study Summary
This multicenter, observational study will evaluate the effectiveness and safety of the NanoKnife System when used for the ablation of Stage 3 pancreatic adenocarcinoma (Stage 3 PC). Eligible patients will be recruited over a 36-month period and participating institutions will enroll and provide data on consecutive patients that meet inclusion and exclusion criteria. Each patient will be followed up for the duration of the study or until death. The study will include two (2) cohorts: patients who received standard of care (SOC) and received irreversible electroporation (IRE) \[IRE cohort\], and patients who were treated with SOC and did not receive IRE \[SOC cohort\].
Conditions Studied
Interventions
- DEVICE NanoKnife System
- DRUG SOC
Study Locations (14)
Florida
- University of Florida Health - Gainesville
- Miami Cancer Institute - Miami
New York
- NYU Langone - New York
- Presbyterian Hospital, Columbia - New York
California
- Moores Cancer Center, UC San Diego Health - La Jolla
Georgia
- Wellstar Medical Group - Marietta
Illinois
- Northwest Community Hospital - Arlington Heights
Iowa
- University of Iowa Healthcare - Iowa City
Kentucky
- Norton Healthcare - Louisville
Minnesota
- Mayo Clinic, Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 532 participants |
| Start Date | 2019-05-08 |
| Est. Completion | 2025-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03899649
The ClinicalTrials.gov registry entry for NCT03899649 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 532 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 126-participant average among 13 other Stage III Pancreatic Cancer trials with a reported enrollment target (322% higher). The listed sponsor is Angiodynamics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Stage III Pancreatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which NanoKnife System is the first listed.
NCT03899649 reports 14 study locations spanning 12 distinct geographic areas - top geographies include Florida, New York, California.
Frequently Asked Questions
What is clinical trial NCT03899649 about?
NCT03899649 is a clinical study titled "A Registry Study of NanoKnife IRE for Stage 3 Pancreatic Cancer". This multicenter, observational study will evaluate the effectiveness and safety of the NanoKnife System when used for the ablation of Stage 3 pancreatic adenocarcinoma (Stage 3 PC). Eligible patients will be recruited over a 36-month period and participating institutions will enroll and provide dat...
What is the current status of trial NCT03899649?
This trial is currently active not recruiting. The enrollment target is 532 participants. The study started on 2019-05-08. Estimated completion is 2025-04.
What conditions does trial NCT03899649 study?
This clinical trial studies the following conditions: Stage III Pancreatic Cancer.
What interventions are being tested in trial NCT03899649?
The interventions under investigation include: NanoKnife System (DEVICE), SOC (DRUG).
Who is sponsoring clinical trial NCT03899649?
This trial is sponsored by Angiodynamics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03899649 being conducted?
This trial has 14 study locations across California, Florida, Georgia, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage III Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
RECRUITING · Phase 2
-
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Malnutrition Screening and Dietary Intervention to Improve Nutrition Outcomes in Patients With Unresectable Pancreatic Cancer
ACTIVE NOT RECRUITING · NA
-
Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.